These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

551 related items for PubMed ID: 26733612

  • 1. Strategically Timing Inhibition of Phosphatidylinositol 3-Kinase to Maximize Therapeutic Index in Estrogen Receptor Alpha-Positive, PIK3CA-Mutant Breast Cancer.
    Yang W, Hosford SR, Dillon LM, Shee K, Liu SC, Bean JR, Salphati L, Pang J, Zhang X, Nannini MA, Demidenko E, Bates D, Lewis LD, Marotti JD, Eastman AR, Miller TW.
    Clin Cancer Res; 2016 May 01; 22(9):2250-60. PubMed ID: 26733612
    [Abstract] [Full Text] [Related]

  • 2. Preclinical modeling of combined phosphatidylinositol-3-kinase inhibition with endocrine therapy for estrogen receptor-positive breast cancer.
    Sanchez CG, Ma CX, Crowder RJ, Guintoli T, Phommaly C, Gao F, Lin L, Ellis MJ.
    Breast Cancer Res; 2011 Mar 01; 13(2):R21. PubMed ID: 21362200
    [Abstract] [Full Text] [Related]

  • 3. Combined Inhibition of Both p110α and p110β Isoforms of Phosphatidylinositol 3-Kinase Is Required for Sustained Therapeutic Effect in PTEN-Deficient, ER+ Breast Cancer.
    Hosford SR, Dillon LM, Bouley SJ, Rosati R, Yang W, Chen VS, Demidenko E, Morra RP, Miller TW.
    Clin Cancer Res; 2017 Jun 01; 23(11):2795-2805. PubMed ID: 27903677
    [Abstract] [Full Text] [Related]

  • 4. Targeting the PI3K/Akt/mTOR pathway with the pan-Akt inhibitor GDC-0068 in PIK3CA-mutant breast cancer brain metastases.
    Ippen FM, Grosch JK, Subramanian M, Kuter BM, Liederer BM, Plise EG, Mora JL, Nayyar N, Schmidt SP, Giobbie-Hurder A, Martinez-Lage M, Carter SL, Cahill DP, Wakimoto H, Brastianos PK.
    Neuro Oncol; 2019 Nov 04; 21(11):1401-1411. PubMed ID: 31173106
    [Abstract] [Full Text] [Related]

  • 5. PIK3CA mutation sensitizes breast cancer cells to synergistic therapy of PI3K inhibition and AMPK activation.
    Liu S, Tang Y, Yan M, Jiang W.
    Invest New Drugs; 2018 Oct 04; 36(5):763-772. PubMed ID: 29504069
    [Abstract] [Full Text] [Related]

  • 6. Autocrine IGF-I/insulin receptor axis compensates for inhibition of AKT in ER-positive breast cancer cells with resistance to estrogen deprivation.
    Fox EM, Kuba MG, Miller TW, Davies BR, Arteaga CL.
    Breast Cancer Res; 2013 Oct 04; 15(4):R55. PubMed ID: 23844554
    [Abstract] [Full Text] [Related]

  • 7. The PI3K/mTOR dual inhibitor P7170 demonstrates potent activity against endocrine-sensitive and endocrine-resistant ER+ breast cancer.
    Bean JR, Hosford SR, Symonds LK, Owens P, Dillon LM, Yang W, Shee K, Schwartz GN, Marotti JD, Muller KE, Rosenkranz KM, Barth RJ, Chen VS, Agarwal VR, Miller TW.
    Breast Cancer Res Treat; 2015 Jan 04; 149(1):69-79. PubMed ID: 25491778
    [Abstract] [Full Text] [Related]

  • 8. Preclinical Efficacy of Ron Kinase Inhibitors Alone and in Combination with PI3K Inhibitors for Treatment of sfRon-Expressing Breast Cancer Patient-Derived Xenografts.
    Bieniasz M, Radhakrishnan P, Faham N, De La O JP, Welm AL.
    Clin Cancer Res; 2015 Dec 15; 21(24):5588-600. PubMed ID: 26289070
    [Abstract] [Full Text] [Related]

  • 9. In pursuit of synergy: An investigation of the PI3K/mTOR/MEK co-targeted inhibition strategy in NSCLC.
    Heavey S, Cuffe S, Finn S, Young V, Ryan R, Nicholson S, Leonard N, McVeigh N, Barr M, O'Byrne K, Gately K.
    Oncotarget; 2016 Nov 29; 7(48):79526-79543. PubMed ID: 27765909
    [Abstract] [Full Text] [Related]

  • 10. Autophagy promotes escape from phosphatidylinositol 3-kinase inhibition in estrogen receptor-positive breast cancer.
    Yang W, Hosford SR, Traphagen NA, Shee K, Demidenko E, Liu S, Miller TW.
    FASEB J; 2018 Mar 29; 32(3):1222-1235. PubMed ID: 29127189
    [Abstract] [Full Text] [Related]

  • 11. Apigenin inhibits antiestrogen-resistant breast cancer cell growth through estrogen receptor-alpha-dependent and estrogen receptor-alpha-independent mechanisms.
    Long X, Fan M, Bigsby RM, Nephew KP.
    Mol Cancer Ther; 2008 Jul 29; 7(7):2096-108. PubMed ID: 18645020
    [Abstract] [Full Text] [Related]

  • 12. More antitumor efficacy of the PI3K inhibitor GDC-0941 in breast cancer with PIK3CA mutation or HER2 amplification status in vitro.
    Zheng J, Wang H, Yao J, Zou X.
    Pharmazie; 2014 Jan 29; 69(1):38-42. PubMed ID: 24601221
    [Abstract] [Full Text] [Related]

  • 13. Aurora kinase B is important for antiestrogen resistant cell growth and a potential biomarker for tamoxifen resistant breast cancer.
    Larsen SL, Yde CW, Laenkholm AV, Rasmussen BB, Duun-Henriksen AK, Bak M, Lykkesfeldt AE, Kirkegaard T.
    BMC Cancer; 2015 Apr 08; 15():239. PubMed ID: 25885472
    [Abstract] [Full Text] [Related]

  • 14. The Dual PI3K/mTOR Pathway Inhibitor GDC-0084 Achieves Antitumor Activity in PIK3CA-Mutant Breast Cancer Brain Metastases.
    Ippen FM, Alvarez-Breckenridge CA, Kuter BM, Fink AL, Bihun IV, Lastrapes M, Penson T, Schmidt SP, Wojtkiewicz GR, Ning J, Subramanian M, Giobbie-Hurder A, Martinez-Lage M, Carter SL, Cahill DP, Wakimoto H, Brastianos PK.
    Clin Cancer Res; 2019 Jun 01; 25(11):3374-3383. PubMed ID: 30796030
    [Abstract] [Full Text] [Related]

  • 15. Alpelisib Plus Fulvestrant in PIK3CA-Altered and PIK3CA-Wild-Type Estrogen Receptor-Positive Advanced Breast Cancer: A Phase 1b Clinical Trial.
    Juric D, Janku F, Rodón J, Burris HA, Mayer IA, Schuler M, Seggewiss-Bernhardt R, Gil-Martin M, Middleton MR, Baselga J, Bootle D, Demanse D, Blumenstein L, Schumacher K, Huang A, Quadt C, Rugo HS.
    JAMA Oncol; 2019 Feb 01; 5(2):e184475. PubMed ID: 30543347
    [Abstract] [Full Text] [Related]

  • 16. Heterogeneity and clinical significance of ESR1 mutations in ER-positive metastatic breast cancer patients receiving fulvestrant.
    Spoerke JM, Gendreau S, Walter K, Qiu J, Wilson TR, Savage H, Aimi J, Derynck MK, Chen M, Chan IT, Amler LC, Hampton GM, Johnston S, Krop I, Schmid P, Lackner MR.
    Nat Commun; 2016 May 13; 7():11579. PubMed ID: 27174596
    [Abstract] [Full Text] [Related]

  • 17. Association of FGFR1 with ERα Maintains Ligand-Independent ER Transcription and Mediates Resistance to Estrogen Deprivation in ER+ Breast Cancer.
    Formisano L, Stauffer KM, Young CD, Bhola NE, Guerrero-Zotano AL, Jansen VM, Estrada MM, Hutchinson KE, Giltnane JM, Schwarz LJ, Lu Y, Balko JM, Deas O, Cairo S, Judde JG, Mayer IA, Sanders M, Dugger TC, Bianco R, Stricker T, Arteaga CL.
    Clin Cancer Res; 2017 Oct 15; 23(20):6138-6150. PubMed ID: 28751448
    [Abstract] [Full Text] [Related]

  • 18. LYN-activating mutations mediate antiestrogen resistance in estrogen receptor-positive breast cancer.
    Schwarz LJ, Fox EM, Balko JM, Garrett JT, Kuba MG, Estrada MV, González-Angulo AM, Mills GB, Red-Brewer M, Mayer IA, Abramson V, Rizzo M, Kelley MC, Meszoely IM, Arteaga CL.
    J Clin Invest; 2014 Dec 15; 124(12):5490-502. PubMed ID: 25401474
    [Abstract] [Full Text] [Related]

  • 19. Pharmacokinetic-pharmacodynamic modeling of tumor growth inhibition and biomarker modulation by the novel phosphatidylinositol 3-kinase inhibitor GDC-0941.
    Salphati L, Wong H, Belvin M, Bradford D, Edgar KA, Prior WW, Sampath D, Wallin JJ.
    Drug Metab Dispos; 2010 Sep 15; 38(9):1436-42. PubMed ID: 20538720
    [Abstract] [Full Text] [Related]

  • 20. Overcoming endocrine resistance due to reduced PTEN levels in estrogen receptor-positive breast cancer by co-targeting mammalian target of rapamycin, protein kinase B, or mitogen-activated protein kinase kinase.
    Fu X, Creighton CJ, Biswal NC, Kumar V, Shea M, Herrera S, Contreras A, Gutierrez C, Wang T, Nanda S, Giuliano M, Morrison G, Nardone A, Karlin KL, Westbrook TF, Heiser LM, Anur P, Spellman P, Guichard SM, Smith PD, Davies BR, Klinowska T, Lee AV, Mills GB, Rimawi MF, Hilsenbeck SG, Gray JW, Joshi A, Osborne CK, Schiff R.
    Breast Cancer Res; 2014 Sep 11; 16(5):430. PubMed ID: 25212826
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 28.